17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGF1β compounds

ABSTRACT

The disclosure includes novel compounds which differ from the known prostaglandins PGF 2 α, PGF 2 β, PGE 2 , PGA 2 , and PGB 2  in that the carbon-carbon double bond in the carboxyl-terminated chain of the novel compounds is in the 4,5-position rather than in the 5,6-position, and in that there is a phenyl or substituted phenyl group in the other chain of the novel compounds. These novel compounds are useful for a variety of pharmacological purposes, including abortion, labor induction, and reduction of gastric secretion.

The present application is a divisional application of Ser. No. 580,747, filed May 27, 1975, now issued as U.S. Pat. No. 4,032,561, on June 28, 1977.

The present invention relates to prostaglandin analogs for which the essential material constituting a disclosure therefor is incorporated by reference here from U.S. Pat. No. 4,032,561, issued June 28, 1977. 

I claim:
 1. An optically active compound of the formula: ##STR1## or a racemic form of that compound and the enantiomer thereof, WHEREIN R₁ is hydrogen or alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive;Wherein M is ##STR2## or ##STR3## wherein R₂ is hydrogen, methyl, or ethyl; WHEREIN E is trans--CH=CH-- or --CH₂ CH₂ --; wherein R₈ is hydrogen and R₉ is hydrogen, methyl, or fluoro, or wherein R₈ and R₉ are both methyl or both fluoro, with the proviso that neither of R₈ and R₉ is methyl when R₂ is methyl or ethyl; Wherein C_(t) H_(2t) represents a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive, between --CR₈ R₉ -- and the ring; and Wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR₃, wherein R₃ is alkyl of one to 4 carbon atoms, inclusive and wherein s is zero, one, 2, or 3 with the proviso that not more than 2 T's are other than alkyl; including alkanoates of 2 to 8 carbon atoms, inclusive, and pharmacologically acceptable salts thereof when R₁ is hydrogen.
 2. An optically active compound according to claim 1, wherein E is trans--CH=CH--, R₁ is hydrogen, methyl, or ethyl, M is ##STR4## s is zero or one, T when present is chloro, fluoro, or trifluoromethyl, R₈ and R₉ are methyl, or R₈ is hydrogen and R₉ is fluoro, and C_(t) H_(2t) is --CH₂ -- or --CH₂ CH₂ --, and pharmacologically acceptable salts thereof when R₁ is hydrogen.
 3. An optically active compound according to claim 1, wherein E is trans--CH=CH--, R₁ is hydrogen, methyl, or ethyl, M is ##STR5## wherein R₂ is hydrogen or methyl, s is zero or one, T when present is chloro, fluoro, or trifluoromethyl, R₈ and R₉ are hydrogen, and C_(t) H_(2t) is --CH₂ -- or --CH₂ CH₂ --, and pharmacologically acceptable salts thereof when R₁ is hydrogen.
 4. cis-4,5-Didehydro-17-phenyl-18,19,20-trinor-PGF₁ β, a compound according to claim 3, wherein R₁, R₂, R₈, and R₉ are hydrogen, s is zero, and C_(t) H_(2t) is --CH₂ --.
 5. cis-4,5-Didehydro-17-phenyl-18,19,20-trinor-PGF₁ β, methyl ester, a compound according to claim 3, wherein R₁ is methyl, R₂, R₈, and R₉ are hydrogen, s is zero, and C_(t) H_(2t) is --CH₂ --.
 6. cis-4,5-Didehydro-15-methyl-17-phenyl-18,19,20-trinor-PGF₁ β, a compound according to claim 3, wherein R₁, R₈, and R₉ are hydrogen, R₂ is methyl, s is zero, and C_(t) H_(2t) is --CH₂ --.
 7. cis-4,5-Didehydro-15-methyl-17-phenyl-18,19,20-trinor-PGF₁ β, methyl ester, a compound according to claim 3, wherein R₁ and R₂ are methyl, R₈ and R₉ are hydrogen, s is zero, and C_(t) H_(2t) is --CH₂ --. 